GlassScriptPhysician profile
Tonia Jones
NPI 1457573883
$6,941.50
in general payments reported to CMS, 2019-2025
32 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $1,609 · 2023: $1,757 · 2024: $1,528 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,101.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $713.66 | 2021-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $598.84 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Janssen Biotech, INC. | $535.86 | 2024-2025 | Rybrevant, Carvykti |
| Alexion Pharmaceuticals, INC. | $488.31 | 2022 | |
| Csl Behring | $475.34 | 2022-2025 | Hizentra |
| Karyopharm Therapeutics INC. | $343.41 | 2022-2023 | Xpovio |
| Neurocrine Biosciences, INC. | $290.50 | 2023-2025 | Ingrezza |
| Paratek Pharmaceuticals, INC. | $249.24 | 2022-2023 | Nuzyra |
| Eisai INC. | $237.82 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $229.62 | 2022-2023 | Reblozyl |
| Abbvie INC. | $208.80 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.10 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $134.38 | 2025 | Pyrukynd |
| Horizon Therapeutics Plc | $131.46 | 2023 | Tepezza |
| Cti Biopharma Corp. | $130.64 | 2023 | Vonjo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Airsupra |
| Glaxosmithkline, LLC. | $124.80 | 2024 | Ojjaara |
| Incyte Corporation | $124.06 | 2023 | Jakafi |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2024 | |
| Viiv Healthcare Company | $123.03 | 2024 | |
| Shionogi INC | $122.58 | 2024 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.86 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.36 | 2024 | Xifaxan |
| Gilead Sciences, INC. | $120.90 | 2025 | Trodelvy |
| Lundbeck LLC | $120.83 | 2025 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $120.41 | 2022 | |
| Braeburn INC. | $116.32 | 2024 | Brixadi |
| Genmab U.S., INC. | $116.25 | 2023 | Epkinly |
| Syndax Pharmaceuticals, INC. | $115.19 | 2025 | Revuforj |
| Alkermes, INC. | $109.43 | 2022 | |
| Beone Medicines USA, INC. | $98.31 | 2025 | Brukinsa |
| Pharmaessentia USA Corporation | $86.13 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonia Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.